Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TransMedics (TMDX) Revenue (2018 - 2026)

TransMedics has reported Revenue over the past 8 years, most recently at $160.8 million for Q4 2025.

  • For Q4 2025, Revenue rose 32.18% year-over-year to $160.8 million; the TTM value through Dec 2025 reached $605.5 million, up 37.13%, while the annual FY2025 figure was $605.5 million, 37.13% up from the prior year.
  • Revenue for Q4 2025 was $160.8 million at TransMedics, up from $143.8 million in the prior quarter.
  • Over five years, Revenue peaked at $160.8 million in Q4 2025 and troughed at $5.4 million in Q3 2021.
  • A 5-year average of $70.6 million and a median of $59.4 million in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: plummeted 32.11% in 2021 and later skyrocketed 374.47% in 2022.
  • Year by year, Revenue stood at $8.5 million in 2021, then surged by 267.17% to $31.4 million in 2022, then soared by 158.72% to $81.2 million in 2023, then surged by 49.83% to $121.6 million in 2024, then soared by 32.18% to $160.8 million in 2025.
  • Business Quant data shows Revenue for TMDX at $160.8 million in Q4 2025, $143.8 million in Q3 2025, and $157.4 million in Q2 2025.